ANG Lifesciences

{
  "main_header": {
    "sid": 1002820,
    "name": "ANG Lifesciences",
    "stock_name": "ANG Lifesciences",
    "full_name": "ANG Lifesciences India Ltd",
    "name_url": "stocks-analysis/ang-lifesciences",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "29.87",
    "chg": -0.68,
    "chgp": "-2.23%",
    "dir": -1,
    "prev_price": "30.55",
    "mcapval": "40.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540694,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE236W01016",
    "curr_date": "Jun 19, 03:30 PM",
    "curr_time": "23:06 PM",
    "last_traded_at": "Jun 19, 03:30 PM IST",
    "bse_nse_vol": "2.68 k",
    "exc_status": "Active",
    "traded_date": "Jun 19, 2026",
    "traded_date_str": "2026 06 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ang-lifesciences-1002820-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Golden Cross Forms in ANG Lifesciences India Ltd — On a Day the Stock Fell 2.55%. What the Mixed Signals Mean",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ang-lifesciences-india-ltd-forms-golden-cross-indicating-potential-bullish-breakout-4061855",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ANGLifesciences_goldencross_4061855.png",
        "date": "2026-06-18 18:00:52",
        "description": "The 50-day moving average has crossed above the 200-day moving average for ANG Lifesciences India Ltd, signalling a golden cross on 18 Jun 2026. Yet, the stock declined 2.55% on the same day, while monthly technical indicators remain only mildly bullish or neutral. This divergence between the moving averages and price action calls for a closer examination of the signal’s reliability."
      },
      {
        "title": "ANG Lifesciences India Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ang-lifesciences-india-ltd-is-rated-sell-4061140",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ANGLifesciences_mojoScore_4061140.png",
        "date": "2026-06-18 10:10:04",
        "description": "ANG Lifesciences India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook."
      },
      {
        "title": "ANG Lifesciences Gains 6.88%: Quarterly Turnaround and Market Challenges Shape the Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ang-lifesciences-gains-688-quarterly-turnaround-and-market-challenges-shape-the-week-4051979",
        "imagepath": "",
        "date": "2026-06-13 16:12:39",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>1 June:</strong> Strong quarterly turnaround reported with 39.7% revenue growth</p>\n                    <p><strong>2 June:</strong> Stock continued upward momentum, gaining 2.74%</p>\n                    <p><strong>3 June:</strong> Minor pullback of 0.31% amid mixed market sentiment</p>\n                    <p><strong>4 June:</strong> Decline of 2.61% as market showed resilience</p>\n                    <p><strong>5 June:</strong> Sharp rebound with 4.25% gain, closing the week at Rs.29.19</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.27.31</div></div>\n  ..."
      },
      {
        "title": "Are ANG Lifesciences India Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-ang-lifesciences-india-ltd-latest-results-good-or-bad-4028109",
        "imagepath": "",
        "date": "2026-06-01 19:28:36",
        "description": "ANG Lifesciences India Ltd's latest financial results for Q1 FY27 present a mixed picture of operational performance and ongoing challenges. The company reported net sales of ₹23.50 crores, reflecting a year-on-year growth of 39.71% and a sequential increase of 25.47%. This growth suggests a recovery in demand conditions after a period of revenue volatility. However, despite this revenue growth, the company continues to face significant profitability issues, as evidenced by a net loss of ₹1.38 crores, which, while 70.95% lower than the previous quarter's loss, still indicates persistent financial struggles.\n\nThe operating margin, excluding other income, improved to 11.36%, marking the highest level in eight quarters. This improvement is attributed to better cost management, particularly a reduction in employee costs. Nevertheless, the path from operating profit to net profit remains fraught with challenges,..."
      },
      {
        "title": "ANG Lifesciences Q1 FY27: Marginal Improvement Masks Deeper Structural Challenges",
        "link": "https://www.marketsmojo.com/news/result-analysis/ang-lifesciences-q1-fy27-marginal-improvement-masks-deeper-structural-challenges-4026892",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ANGLifesciences_quaterlyResult_4026892.png",
        "date": "2026-06-01 12:53:23",
        "description": "ANG Lifesciences India Limited reported a net loss of ₹1.38 crores for Q1 FY27 (April-June 2026), narrowing from a ₹4.75 crores loss in the previous quarter. Despite a 25.47% quarter-on-quarter revenue increase to ₹23.50 crores, the Amritsar-based pharmaceutical company continues to grapple with persistent profitability challenges that have plagued operations for over three years. The stock surged 7.84% to ₹29.45 following the results announcement, though the micro-cap company's market capitalisation remains modest at ₹38.46 crores."
      },
      {
        "title": "ANG Lifesciences India Ltd Reports Strong Quarterly Turnaround Amid Persistent Long-Term Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ang-lifesciences-india-ltd-reports-strong-quarterly-turnaround-amid-persistent-long-term-challenges-4026589",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ANGLifesciences_fintrenddot_4026589.png",
        "date": "2026-06-01 12:01:31",
        "description": "ANG Lifesciences India Ltd has demonstrated a notable improvement in its financial performance for the quarter ended March 2026, reversing a previously negative trend. The company’s revenue growth, margin expansion, and profitability metrics have all shown encouraging signs, signalling a potential shift in its operational trajectory despite ongoing market challenges."
      },
      {
        "title": "Are ANG Lifesciences India Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-ang-lifesciences-india-ltd-latest-results-good-or-bad-4023921",
        "imagepath": "",
        "date": "2026-05-30 19:52:21",
        "description": "The latest financial results for ANG Lifesciences India Ltd indicate significant operational challenges and a concerning trend in its performance. For the quarter ended December 2025, the company reported net sales of ₹18.73 crores, reflecting a year-on-year decline of 24.26%. This marks the lowest quarterly revenue in the past eight quarters, highlighting persistent issues with market demand or product competitiveness.\n\nThe company also faced a net loss of ₹4.75 crores during this period, which represents a substantial deterioration compared to previous quarters. The operating margin was recorded at -14.36%, the lowest in eight quarters, indicating severe profitability challenges. These results underscore a broader trend of declining revenues and mounting losses, with the company experiencing a five-year revenue decline of approximately 30.82%.\n\nAdditionally, ANG Lifesciences has seen its debt levels rise,..."
      },
      {
        "title": "ANG Lifesciences India Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ang-lifesciences-india-ltd-is-rated-strong-sell-4016471",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ANGLifesciences_mojoScore_4016471.png",
        "date": "2026-05-27 10:11:05",
        "description": "ANG Lifesciences India Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 Jun 2023. However, the analysis and financial metrics discussed here reflect the company’s current position as of 27 May 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "ANG Lifesciences India Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ang-lifesciences-india-ltd-is-rated-strong-sell-3989320",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ANGLifesciences_mojoScore_3989320.png",
        "date": "2026-05-13 10:10:31",
        "description": "ANG Lifesciences India Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 Jun 2023. However, the analysis and financial metrics discussed here reflect the company’s current position as of 13 May 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook."
      }
    ],
    "total": 304,
    "sid": "1002820",
    "stock_news_url": "https://www.marketsmojo.com/news/ang-lifesciences-india-1002820"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "05-Jun-2026",
      "details": "Newspaper Publication of Audited Financial Results for the quarter and year ended March 31 2026.",
      "source": "BSE"
    },
    {
      "caption": "Results - 31.03.2026",
      "datetime": "30-May-2026",
      "details": "Audited Results 31.03.2026",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Board Meeting Outcome For Audited Financial Results For The Quarter And Year Ended 31St March 2026",
      "datetime": "30-May-2026",
      "details": "Audited Financial Results for the quarter and year ended 31st March 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "ANG Lifesciences India Ltd has declared <strong>10%</strong> dividend, ex-date: 02 Nov 21",
          "dt": "2021-11-02",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "ANG Lifesciences India Ltd has announced <strong>1:4</strong> bonus issue, ex-date: 13 Jul 22",
          "dt": "2022-07-13",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Golden Cross Forms in ANG Lifesciences India Ltd — On a Day the Stock Fell 2.55%. What the Mixed Signals Mean

2026-06-18 18:00:52

The 50-day moving average has crossed above the 200-day moving average for ANG Lifesciences India Ltd, signalling a golden cross on 18 Jun 2026. Yet, the stock declined 2.55% on the same day, while monthly technical indicators remain only mildly bullish or neutral. This divergence between the moving averages and price action calls for a closer examination of the signal’s reliability.

Read full news article

ANG Lifesciences India Ltd is Rated Sell

2026-06-18 10:10:04

ANG Lifesciences India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article

ANG Lifesciences Gains 6.88%: Quarterly Turnaround and Market Challenges Shape the Week

2026-06-13 16:12:39

Key Events This Week

1 June: Strong quarterly turnaround reported with 39.7% revenue growth

2 June: Stock continued upward momentum, gaining 2.74%

3 June: Minor pullback of 0.31% amid mixed market sentiment

4 June: Decline of 2.61% as market showed resilience

5 June: Sharp rebound with 4.25% gain, closing the week at Rs.29.19

Week Open

Rs.27.31

...

Read full news article

Are ANG Lifesciences India Ltd latest results good or bad?

2026-06-01 19:28:36

ANG Lifesciences India Ltd's latest financial results for Q1 FY27 present a mixed picture of operational performance and ongoing challenges. The company reported net sales of ₹23.50 crores, reflecting a year-on-year growth of 39.71% and a sequential increase of 25.47%. This growth suggests a recovery in demand conditions after a period of revenue volatility. However, despite this revenue growth, the company continues to face significant profitability issues, as evidenced by a net loss of ₹1.38 crores, which, while 70.95% lower than the previous quarter's loss, still indicates persistent financial struggles. The operating margin, excluding other income, improved to 11.36%, marking the highest level in eight quarters. This improvement is attributed to better cost management, particularly a reduction in employee costs. Nevertheless, the path from operating profit to net profit remains fraught with challenges,...

Read full news article

ANG Lifesciences Q1 FY27: Marginal Improvement Masks Deeper Structural Challenges

2026-06-01 12:53:23

ANG Lifesciences India Limited reported a net loss of ₹1.38 crores for Q1 FY27 (April-June 2026), narrowing from a ₹4.75 crores loss in the previous quarter. Despite a 25.47% quarter-on-quarter revenue increase to ₹23.50 crores, the Amritsar-based pharmaceutical company continues to grapple with persistent profitability challenges that have plagued operations for over three years. The stock surged 7.84% to ₹29.45 following the results announcement, though the micro-cap company's market capitalisation remains modest at ₹38.46 crores.

Read full news article

ANG Lifesciences India Ltd Reports Strong Quarterly Turnaround Amid Persistent Long-Term Challenges

2026-06-01 12:01:31

ANG Lifesciences India Ltd has demonstrated a notable improvement in its financial performance for the quarter ended March 2026, reversing a previously negative trend. The company’s revenue growth, margin expansion, and profitability metrics have all shown encouraging signs, signalling a potential shift in its operational trajectory despite ongoing market challenges.

Read full news article

Are ANG Lifesciences India Ltd latest results good or bad?

2026-05-30 19:52:21

The latest financial results for ANG Lifesciences India Ltd indicate significant operational challenges and a concerning trend in its performance. For the quarter ended December 2025, the company reported net sales of ₹18.73 crores, reflecting a year-on-year decline of 24.26%. This marks the lowest quarterly revenue in the past eight quarters, highlighting persistent issues with market demand or product competitiveness. The company also faced a net loss of ₹4.75 crores during this period, which represents a substantial deterioration compared to previous quarters. The operating margin was recorded at -14.36%, the lowest in eight quarters, indicating severe profitability challenges. These results underscore a broader trend of declining revenues and mounting losses, with the company experiencing a five-year revenue decline of approximately 30.82%. Additionally, ANG Lifesciences has seen its debt levels rise,...

Read full news article

ANG Lifesciences India Ltd is Rated Strong Sell

2026-05-27 10:11:05

ANG Lifesciences India Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 Jun 2023. However, the analysis and financial metrics discussed here reflect the company’s current position as of 27 May 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

ANG Lifesciences India Ltd is Rated Strong Sell

2026-05-13 10:10:31

ANG Lifesciences India Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 Jun 2023. However, the analysis and financial metrics discussed here reflect the company’s current position as of 13 May 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

View All News